Department of Pharmacology and Toxicology, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan.
BMC Pulm Med. 2024 Sep 14;24(1):453. doi: 10.1186/s12890-024-03274-5.
This study aimed to determine the prevalence of polypharmacy, comorbidities and to investigate factors associated with polypharmacy among adult patients with Chronic Obstructive Pulmonary Disease (COPD).
This was a retrospective single-centre cross-sectional study. Patients with a confirmed diagnosis of COPD according to the GOLD guidelines between 28 February 2020 and 1 March 2023 were included in this study. Patients were excluded if a pre-emptive diagnosis of COPD was made clinically without spirometry evidence of fixed airflow limitation. Population characteristics were presented as frequency for categorical variable. Logistic regression analysis was used to identify predictors of polypharmacy.
The study sample included a total of 705 patients with COPD. Most of the study sample were males (60%). The mean age of the study population was 65 years old. The majority of the study population had comorbid diseases (68%), hypertension and diabetes were the most common co-existent diseases. Around 55% of the study sample had polypharmacy. Females were significantly less likely to be on polypharmacy compared to males (OR = 0.68, 95% CI = [0.50-0.92], P-value = 0.012)). On the other hand, older patients aged 65.4 or more (OR = 2.31, 95% CI = [1.71-3.14], P-value ≤ 0.001), those with high BMI (≥ 29.2) (OR = 1.42, 95% CI = [1.05-1.92], P-value = 0.024), current smokers (OR = 1.9, 95% CI = [1.39-2.62], P-value ≤ 0.001), those who are receiving home care (OR = 5.29, 95% CI = [2.46-11.37], P-value ≤ 0.001), those who have comorbidities (OR = 19.74, 95% CI = [12.70-30.68], P-value ≤ 0.001) were significantly more likely to be on polypharmacy (p ≤ 0.05).
Polypharmacy is common among patients with COPD. Patients with high BMI, previous ICU hospitalization and older age are more likely to have polypharmacy. Future analytical studies are warranted to investigate outcomes in patients with COPD and polypharmacy.
本研究旨在确定成人慢性阻塞性肺疾病（COPD）患者中同时使用多种药物的流行率、合并症，并探讨与同时使用多种药物相关的因素。
这是一项回顾性单中心横断面研究。纳入 2020 年 2 月 28 日至 2023 年 3 月 1 日期间根据 GOLD 指南确诊为 COPD 的患者。如果根据肺量计证据预先诊断 COPD 存在固定气流受限，而无临床诊断，则排除患者。人口特征以分类变量的频率表示。采用 logistic 回归分析识别同时使用多种药物的预测因素。
本研究样本共包括 705 名 COPD 患者。研究样本中大多数为男性（60%）。研究人群的平均年龄为 65 岁。研究人群中大多数患有合并症（68%），高血压和糖尿病是最常见的并存疾病。约 55%的研究样本同时使用多种药物。与男性相比，女性同时使用多种药物的可能性显著降低（OR=0.68，95%CI=[0.50-0.92]，P 值=0.012）。另一方面，年龄在 65.4 岁或以上（OR=2.31，95%CI=[1.71-3.14]，P 值≤0.001）、体重指数较高（≥29.2）（OR=1.42，95%CI=[1.05-1.92]，P 值=0.024）、目前吸烟（OR=1.9，95%CI=[1.39-2.62]，P 值≤0.001）、接受家庭护理（OR=5.29，95%CI=[2.46-11.37]，P 值≤0.001）、合并症（OR=19.74，95%CI=[12.70-30.68]，P 值≤0.001）的患者更有可能同时使用多种药物（p≤0.05）。
同时使用多种药物在 COPD 患者中很常见。体重指数较高、曾住 ICU 病房和年龄较大的患者更有可能同时使用多种药物。有必要进行进一步的分析研究，以调查 COPD 合并同时使用多种药物患者的结局。
